Corbevax

Corbevax is a protein subunit vaccine developed by Biological E. Limited, an Indian biopharmaceutical company. The vaccine is designed to prevent COVID-19, a disease caused by the SARS-CoV-2 virus.

Development

The development of Corbevax began in 2020, in response to the global COVID-19 pandemic. The vaccine was developed using a protein subunit platform, a well-established vaccine technology that has been used in other vaccines such as the hepatitis B vaccine. The vaccine contains the recombinant spike protein of the SARS-CoV-2 virus, which triggers an immune response in the body.

Clinical Trials

Corbevax underwent three phases of clinical trials to assess its safety and efficacy. The Phase I and II trials demonstrated that the vaccine was safe and well-tolerated, and the Phase III trial, which involved over 30,000 participants, showed that the vaccine had an efficacy rate of over 90%.

Authorization and Distribution

Corbevax received emergency use authorization from the Drug Controller General of India (DCGI) in December 2021. The vaccine is expected to play a significant role in India's vaccination drive, due to its low cost and ease of storage and distribution.

Effectiveness

Corbevax has been shown to be effective against the original strain of the SARS-CoV-2 virus, as well as several of its variants. However, ongoing research is being conducted to assess its effectiveness against newer variants of the virus.

Side Effects

Common side effects of Corbevax include pain at the injection site, fatigue, headache, muscle pain, and fever. These side effects are typically mild and resolve within a few days.

See Also

• COVID-19 vaccine
• COVID-19 pandemic in India
• Vaccine trial
• Biological E. Limited